[Corrections] Correction to Lancet Infect Dis 2024; published online March 22. https://doi.org/10.1016/S1473-3099(24)00154-3

Di |2024-03-30T00:30:01+01:00Marzo 30th, 2024|Categorie: Coronavirus Lancet|

Dinkele R, Khan PY, Warner DF. Mycobacterium tuberculosis transmission: the importance of precision. Lancet Infect Dis 2024; published online March 22. https://doi.org/10.1016/S1473-3099(24)00154-3—In this Comment, the particle size of microscopic pauc...

[Corrections] Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5

Di |2024-03-28T00:30:06+01:00Marzo 28th, 2024|Categorie: Coronavirus Lancet|

Bertan M, D'Aeth JC, Abdullahi F, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance stu...

[Articles] Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Di |2024-03-27T00:30:07+01:00Marzo 27th, 2024|Categorie: Coronavirus Lancet|

Overall, the vaccine regimen and booster dose were well tolerated. A similar and robust humoral immune response was observed for participants boosted 1 year and 2 years after the first dose, supporting the use of the regimen and flexibility of booster ...

Torna in cima